Efficacy of Intravenous Fluconazole Prophylaxis on Outcomes of Very-Low-Birth-Weight Infants Admitted to the Neonatal Intensive Care Unit: A Randomized Clinical Trial | ||
| Journal of Integrated Maternal and Pediatric Care | ||
| Volume 9, Issue 1, September 2026, Pages 46-52 PDF (300.44 K) | ||
| Document Type: Original Article | ||
| DOI: 10.18502/jimpc.v9i1.22984 | ||
| Authors | ||
| Farzaneh Shakeri1; Seyed Reza Mirjalili* 2; Naeimeh Naserzadeh3; Mahmood Noorishadkam2; Mohamad Hosein Lookzadeh2; Arefeh Dehghani Tafti4; Mohammadtaha Nourishadkam5 | ||
| 1School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran | ||
| 2Mother and Newborn Health Research Center, Comprehensive Research institute for Maternal and Child Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran | ||
| 3Children Growth Disorder Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran | ||
| 4Department of Biostatistics and Epidemiology, Center for Healthcare Data Modeling, Shahid Sadoughi University of Medical Sciences, Yazd, Iran | ||
| 5University of Medicine and Pharmacy "Grigore T. Popa", Lasi, Romania | ||
| Abstract | ||
| Background: Invasive fungal infections (IFIs) cause morbidity and mortality in very-low-birth-weight (VLBW) infants, but routine fluconazole prophylaxis remains controversial in low-prevalence units. We evaluated intravenous fluconazole prophylaxis in VLBW infants. Methods: In this randomized, open-label trial, 80 infants with birth weight <1500 g and gesta-tional age ≥25 weeks admitted to a NICU in Yazd, Iran (2020–2021) received intravenous fluconazole (3 mg/kg twice weekly for 4 weeks; n=40) or standard care (n=40). The primary outcome was IFI (positive blood culture at week 4). Secondary outcomes included respiratory morbidity, necrotizing enterocolitis, bronchopulmonary dysplasia, intraventricular hemorrhage, retinopathy of prematurity, hematological indices, length of stay, and mortality. Results: IFI occurred in one fluconazole-treated infant (2.5%) versus none (0%) in controls (P=1.000); overall prevalence was 1.25% (1/80). Because only one IFI occurred, the trial was underpowered. In unadjusted analyses, the fluconazole group had higher rates of bronchopul-monary dysplasia (40% vs 17.5%, P=0.047), apnea (45% vs 20%, P=0.031), necrotizing enterocolitis (40% vs 17.5%, P=0.047), longer respiratory support (28.18 vs 19.72 days, P=0.047), and third-week neutropenia (15% vs 0%, P=0.026). However, the fluconazole group had lower gesta-tional age (29.1 vs 30.6 weeks; P=0.0036) and birth weight (1082 vs 1222 g; P=0.0035). Adjusted GEE analyses showed no significant effect on hematological trajectories. Mortality, intraventric-ular hemorrhage, retinopathy of prematurity, and length of stay did not differ. No hepatotoxicity occurred. Conclusion: In this low-endemicity NICU, routine fluconazole prophylaxis did not demonstrate reduced IFI, but the study was underpowered. Baseline differences may explain crude morbidity. These findings do not support prophylaxis. | ||
| Keywords | ||
| Fluconazole; Antifungal Agents; Very Low Birth Weight Infant; Invasive Candidiasis; Intensive Care Units | ||
| References | ||
|
| ||
|
Statistics Article View: 100 PDF Download: 29 |
||